Macular translocation is still effective after five years

Article

It is possible for AMD patients to maintain BCVA for fives years after macular translocation surgery..

According to data published in the journal Eye it is possible for AMD patients to maintain BCVA for five years after macular translocation surgery.

A team led by Dr K. Takeuchi, Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan, assessed the medical records of 61 consecutive patients who experienced macular translocation.

Of the patients included in the study, 35 eyes were treated for AMD and 26 eyes were treated for myopic choroidal neovascularisation (mCNV). Area of the Goldmann visual field (VF) and BCVA were measured before surgery, 12 months after surgery and at the final follow-up.

In the AMD eyes the mean preoperative BCVA was 1.149±0.105 logMAR, improving to 0.69±0.06 logMAR 1 year postoperatively. The BCVA was maintained at 0.633±0.083 logMAR at the final follow-up visit.

In the mCNV eyes the mean preoperative BCVA was 1.083±0.119 logMAR, improving to 0.689±0.121 logMAR one year postoperatively. This was maintained at 0.678±0.142 logMAR at the final follow-up.

For both groups the area of the VF was significantly reduced at 12 months postoperatively and did not change significantly over the following five years.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.